
|Videos|September 9, 2021
Should anti-VEGF agents be used to treat patients with NPDR?
Author(s)OT Staff Reports
Jennifer Sun, MD, MPH, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Advertisement
Jennifer Sun, MD, MPH, associate professor of Ophthalmology, Harvard Medical School; chief at the Center for Clinical Eye Research and Trials, Joslin Diabetes Center, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
2
Optigo: Lead anti-VEGF program advancing toward IND-enabling studies
3
Q&A: Stephen Tsang discusses outcomes in retinitis pigmentosa and Stargardt trials
4
Q&A: Diana Do shares real world insights on aflibercept 8 mg
5

















































